3 Healthcare Tech Stocks Riding The AI Clinical Trials Shift

AI is creeping into the most expensive part of drug development, the clinical trial, and that shift is starting to influence which tickers investors watch and which they avoid. As virtual studies, predictive trial engines and new U.S. regulatory pushes reshape how R&D capital is spent, you risk missing the next wave of winners or backing the wrong stories. This article breaks down 3 stocks exposed to this AI clinical trials news, explaining how each could benefit or face added scrutiny so you can judge whether they deserve a closer look.

The three stocks in focus are only a starting sample, as the full screen surfaced 43 more publicly listed businesses tied to AI trials, real world data and RegTech with equally compelling narratives that are not covered here. To identify and analyze the highest conviction angles across that broader set, head straight into the AI-Driven Clinical Trials & Regulatory Tech screener.

NNIT (CPSE:NNIT)

Overview: NNIT provides IT and consulting services for life sciences clients, covering clinical systems, regulatory compliance, data management, cybersecurity and cloud.

Operations: NNIT generates most revenue in Denmark at DKK 697 million and Europe at DKK 585 million, with smaller contributions from the US and Asia.

Market Cap: DKK 843 million

For investors focused on AI clinical trials and regulatory tech, NNIT matters because it supplies the plumbing that keeps digital trial and compliance workflows running reliably.

"The integration of acquisitions and completion of new ERP and HR systems in 2024 are expected to streamline operations and lower costs, positively impacting net margins."

What really moves the needle for NNIT now is how one quiet shift in its life sciences client demand pattern ultimately lands on margins.

That margin question is exactly what the full narrative for NNIT unpacks, showing where efficiency gains could accelerate, where they may stall, and how life sciences demand really feeds through.

Tecan Group (SWX:TECN)

Overview: Tecan Group supplies automated lab instruments, consumables and software that help biopharma and clinical diagnostics customers run data heavy, AI ready workflows.

Operations: Tecan Group generates about CHF 501 million from its Partnering Business and CHF 378 million from its Life Sciences Business, with substantial sales across the Americas, EMEA and APAC.

Market Cap: CHF 3.0b

In the AI driven clinical trials theme, Tecan Group matters because its hardware and software sit where samples turn into structured data that feed predictive models and regulatory filings.

"Tecan's focus on launching advanced, end-to-end workflow automation platforms (for example, the Veya workstation and Duo Digital Dispenser) and proprietary software positions the company to benefit from increased digital transformation and data analytics in healthcare, which may support premium pricing and margin expansion.

The real swing factor is how one underappreciated cost and pricing pressure shapes what those higher value workflows mean for future profitability.

That pricing squeeze is exactly what the full narrative for Tecan Group pulls apart, mapping where automation could accelerate earnings power and where rising costs risk quietly stalling profitability.

Cosmo (SWX:CMHC)

Overview: Cosmo develops gastrointestinal and dermatology medicines alongside GI Genius, an AI endoscopy platform that plugs directly into real-world clinical workflows.

Operations: Cosmo currently generates about €103 million from its Pharmaceuticals segment, which anchors funding for its AI and health tech efforts.

Market Cap: CHF915 million

Cosmo matters for this AI-driven clinical trials and regulatory tech theme because its GI Genius platform already shapes how clinicians capture, structure and use procedure data inside everyday care.

"The latest version of Cosmo's polyp detection software is now even more accurate, providing AI-generated information after the procedure, reaffirming Cosmo's leadership in AI-enhanced endoscopy."

What could really shift the story for Cosmo is how one emerging source of recurring software demand interacts with its existing drug portfolio economics.

That tension between recurring software pull and drug economics is exactly what the full narrative for Cosmo unpacks, revealing how Cosmo's AI engine could accelerate or quietly cap long term value.

Seeking Alternatives Before Momentum Flies

Fresh ideas move first. By the time momentum headlines hit, early entry points are already dropping away. Scan under the radar for now and act now.

• Spot cash rich compounders before they get crowded by screening a curated list of solid balance sheet and fundamentals (206 results) that keeps weak balance sheets out of your watchlist.
• Hunt real income plays while yields are still flying under most radars by focusing on a filtered group of 169 dividend fortresses built for durability.
• Track where AI demand could break out next through a tight collection of 91 AI infrastructure stocks that connect directly to growing compute and data center spending.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com